What is Nanobiotix (NBTX) stock price today?

Nanobiotix (NBTX) currently trades at $32.99 per share. The stock has a market capitalization of $1.60B and a P/E ratio of —x.

Is NBTX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Nanobiotix has a Smart Value Score of 22/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -1.59.

What is Nanobiotix's revenue and earnings?

Nanobiotix has trailing twelve-month (TTM) revenue of $32.59M with profit margins of -73.50%. Earnings per share (EPS) is $-0.59.

Is Nanobiotix financially healthy?

Nanobiotix's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -1.59 places it in the distress.

NBTX

Nanobiotix

NASDAQ: NBTX · HEALTHCARE · BIOTECHNOLOGY

$32.99

-0.39% today

Updated 2026-04-29

Market cap

$1.60B

P/E ratio

—

P/S ratio

49.09x

EPS (TTM)

$-0.59

Dividend yield

—

52W range

$3 – $42

Volume

0.1M

Market cap

$1.60B

P/E ratio

—

P/S ratio

49.09x

EPS (TTM)

$-0.59

Dividend yield

—

52W range

$3 – $42

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

8.0

Growth

4.5

Quality

2.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-1.6

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$34.21

+3.70%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 186.80% QoQ

+ Debt/equity -0.74x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -1.59 — distress zone

- Thin margins at -73.50%

- Negative free cash flow $-16.41M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$4.78M	$36.21M	$-7.19M	$29.64M	$32.59M
Net income	$-57.04M	$-39.70M	$-68.13M	$-23.96M	$-18.58M
EPS	—	—	—	—	$-0.59
Free cash flow	$-37.20M	$-12.80M	$-20.40M	$-33.97M	$-16.41M
Profit margin	-1,194.33%	-109.64%	947.59%	-80.83%	-73.50%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
NBTX	$1.60B	22	8.0	2.0	5.0	4.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Nanobiotix trades at $32.99. Our Smart Value Score of 22/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -1.59, it sits in the distress. TTM revenue stands at $32.59M. with profit margins at -73.50%.

Frequently asked questions

What is Nanobiotix's stock price?

Nanobiotix (NBTX) trades at $32.99.

Is Nanobiotix overvalued?

Smart Value Score 22/100 (Grade F, Strong Sell).

What is the price target of Nanobiotix (NBTX)?

The analyst target price is $34.21, representing +3.7% upside from the current price of $32.99.

What is Nanobiotix's revenue?

TTM revenue is $32.59M.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-1.59 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.nanobiotix.com

Quick metrics

P/S ratio49.09x

ROE-198.70%

Beta0.55

50D MA$31.44

200D MA$20.73

Shares out0.05B

Float0.03B

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

NBTX vs LLY →NBTX vs JNJ →NBTX vs ABBV →Stock screener →